Search results
Bristol Myers' Opdivo extends survival in bladder cancer study
Reuters via AOL· 11 months agoThe drug met the dual main goals of extending overall survival and helping patients live without...
Bristol Myers' injectable form of Opdivo meets main goal in kidney cancer trial
Reuters via AOL· 8 months agoThe new formulation of the drug that was tested in the trial used Halozyme Therapeutics' proprietary...
Bristol Myers' (BMY) Opdivo SC Meets Kidney Cancer Study Goals
Zacks via Yahoo Finance· 8 months agoBristol Myers' (BMY) subcutaneous formulation of Opdivo, developed using Halozyme's Enhanze...
Bristol Myers' (BMY) Opdivo With Chemo Gets EC Nod for NSCLC
Zacks via Yahoo Finance· 12 months agoBristol Myers' (BMY) Opdivo, in combination with chemotherapy, gains European Commission approval...
Bristol Myers' (BMY) Opdivo Meets Main Goal in Melanoma Study
Zacks via Yahoo Finance· 2 years agoBristol Myers' (BMY) immuno-oncology drug Opdivo demonstrates a statistically significant and...
Bristol Myers gets positive data in subcutaneous Opdivo trial
BioPharma Dive via Yahoo Finance· 5 months agoAn under-the-skin Opdivo shot produced similar results to an intravenous formulation in kidney...
Exeliom to focus on gastric cancer landscape with immune modulating drug
Clinical Trials Arena via Yahoo Finance· 2 months agoParis-based Exeliom Biosciences will focus Phase III efforts of its immune modulating drug EXL01 in...
Bristol Myers drug combo fails to meet main goal in kidney cancer trial
Reuters via Yahoo News· 2 years agoYervoy and top selling cancer drug Opdivo - is already approved in the United States as a first line...
Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study
Zacks via Yahoo Finance· 1 month agoBristol Myers' (BMY) late-stage label-expanding study evaluating the Opdivo/Yervoy combination fails...
'Extraordinary' study results offer new hope for advanced lung cancer patients being treated with...
USA TODAY via Yahoo News· 2 years agoPatients with advanced lung cancer had a better chance at survival when their treatment combined...